ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BFRI / dividends
BOLT (37) JAGX (28) HIND (29) BIVI (32) ⌘ Pro Terminal →

Biofrontera Inc. (BFRI) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.87 -6.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.86

Biofrontera Inc. (BFRI) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $13.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BFRI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BFRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Biofrontera Inc. (NASDAQ: BFRI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.87 (-6.29% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BFRI ranks #918 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BFRI compare to BOLT and JAGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BFRI carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BOLT (Bolt Biotherapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and JAGX (Jaguar Health Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BFRI leads on earnings multiple (N/A) while BFRI leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BFRI?
▼

Per BFRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001858685), Biofrontera Inc. generated $41.7M in revenue (+11.7% YoY), -$10.5M in net income, and -$13.4M in free cash flow against $28.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.86 (-1.32%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (5)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.9% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE BFRI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BFRI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY BFRI SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (23% of score)

FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 43.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$0.89-10.1% Next Q
Q2 (-2Q)
31
Grade E$0.80+5% Next Q
Q3 (-1Q)
29
Grade E$0.84+3.6% Next Q
Current
26
Grade E$0.87-10.5% Hist 90D α
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BFRI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BFRI currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.13) and Max Pain ($0.91) forces dealer call-delta covering toward $1.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BFRI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BFRI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (8.2% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $21,992

Est. Year-10 Shareholder Yield: $396/yr
$10.8K
Yr 1
$11.7K
Yr 2
$12.7K
Yr 3
$13.7K
Yr 4
$14.8K
Yr 5
$16.0K
Yr 6
$17.4K
Yr 7
$18.8K
Yr 8
$20.3K
Yr 9
$22.0K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BFRI)

  • ✓Walkthrough of BFRI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BFRI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.62%📐 HORIZONTAL RANGE
2026-11-03O $0.93H $0.93L $0.87C $0.87VOL 302.4K
RES: $1.88SUP: $0.76SMA50: $1.13SMA200: $1.03
$1.73$1.46$1.19$0.92$0.65RES $1.88SUP $0.76$0.872026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BFRI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BFRI Butterfly Map → + Track BFRI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BFRI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BFRI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BFRI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BFRI)

Health Care Rank #918 of 1015 ⚔️ BOLT vs BFRI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BFRI vs. BOLT, JAGX, HIND, BIVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Biofrontera Inc. (BFRI) ranks #918 by composite RQD confidence (26/100, grade E) and #864 by equity capitalization ($13.0M). Within this direct 5-issuer industry benchmark cohort, BFRI leads on earnings valuation at N/A trailing P/E, while BFRI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BOLT currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with BFRI at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BFRI ACTIVE
Biofrontera Inc.
E 26/100 — — -35.0% -6.29% $13.0M Benchmark Subject
BOLT
Bolt Biotherapeutics Inc.
D- 37/100 — — -35.0% +3.62% $12.7M /bolt-vs-bfri →
JAGX
Jaguar Health Inc.
E 28/100 — 67.2% -35.0% -20.59% $12.6M /jagx-vs-bfri →
HIND
Vyome Holdings Inc.
E 29/100 — 68.4% -35.0% +2.86% $12.6M /hind-vs-bfri →
BIVI
BioVie Inc. (Class A)
E 32/100 — — -35.0% +3.62% $12.4M /bivi-vs-bfri →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001858685 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biofrontera Inc. (BFRI) reported GAAP revenue of $41.7M (+11.7% vs. FY2024 revenue of $37.3M , and +22.4% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (-30.0% YoY). On the balance sheet, BFRI closed FY2025 with $28.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $41.7M -$10.5M -$13.4M -$13.4M $28.6M —
FY2024 (FY) 2024-12-31 $37.3M -$17.8M -$10.3M -$10.3M $22.1M —
FY2023 (FY) 2023-12-31 $34.1M -$20.1M -$24.9M -$24.9M — —

3. BFRI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BFRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Biofrontera Inc. (NASDAQ: BFRI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.87 (-6.29% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BFRI ranks #918 in composite RQD confidence.

How does BFRI compare to BOLT and JAGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BFRI carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BOLT (Bolt Biotherapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and JAGX (Jaguar Health Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BFRI leads on earnings multiple (N/A) while BFRI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BFRI?

Per BFRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001858685), Biofrontera Inc. generated $41.7M in revenue (+11.7% YoY), -$10.5M in net income, and -$13.4M in free cash flow against $28.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BFRI trading relative to its 50-day, 200-day, and 52-week technical levels?

BFRI last traded at $0.87 (-6.29% on volume of 302,427 shares), positioning the stock -23.01% below its 50-day simple moving average ($1.13) and -15.53% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.56 to $1.66, BFRI sits at the 28.2% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.98).

Direct Sub-Reports: BFRI RQD Cockpit BFRI 12M Forecast BFRI Earnings & Move BFRI Dividends & DRIP BFRI Insiders & 13F BFRI Whale Options BFRI Profit Sankey BFRI News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

BFRI — Biofrontera Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Biofrontera Inc. (BFRI) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.87 (-6.29% 1D, market capitalization $13.0M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -27.2%, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Biofrontera Inc. (BFRI) is listed on NASDAQ and classified under the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $41.7M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Biofrontera Inc. (BFRI) reported $41.7M in annual revenue (up from $37.3M in FY2024, +11.7% YoY) and -$10.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.1M revenue, -$20.1M net income) through FY2025, BFRI scaled operating cash flow to -$13.4M and free cash flow to -$13.4M, backed by $28.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.56 – $1.66 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -27.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BFRI carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BFRI sustain or expand its -27.2% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $41.7M and free cash flow of -$13.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BFRI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BFRI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Biofrontera Inc. (BFRI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BFRI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BFRI Bull vs. Bear Conversation Board — What's Your Call at $0.87?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BFRI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BFRI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.13 (+29.9%)
📌 Pinned Debate

Revenue grew from $34.1M in FY 2023 to $41.7M in FY 2025 while net losses narrowed from -$20.1M to -$10.5M.

Here is why I am bullish on BFRI here at $0.87: Revenue grew from $34.1M in FY 2023 to $41.7M in FY 2025 while net losses narrowed from -$20.1M to -$10.5M.. Compare BFRI's -27.2% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.83 are getting bought.

CapAlloc_Nerd 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.68 (-21.8%)
Spot @ $0.87

Negative ROIC of -35% and a 0% FCF yield, with FY 2025 free cash flow of -$13.4M, show no current cash generation under the RQD cash-en

Sitting on the sidelines or leaning short BFRI above $0.87. Negative ROIC of -35% and a 0% FCF yield, with FY 2025 free cash flow of -$13.4M, show no current cash generation under the RQD cash-engine pillar.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.66.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%